Development of a humanized antibody with high therapeutic potential against dengue virus type 2

PLoS Neglected Tropical Diseases

Volumn 6, Issue 5, 2012, Pages

  Li, Pi Chun ^a,b   Liao, Mei Ying ^b   Cheng, Ping Chang ^b   Liang, Jian Jong ^c   Liu, I Ju ^b   Chiu, Chien Yu ^b   Lin, Yi Ling ^c   Chang, Gwong Jen J ^d   Wu, Han Chung ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DB32 6 PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; DENGUE; DENGUE VIRUS 2; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE TEST; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; SURFACE PLASMON RESONANCE; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DENGUE VIRUS; DISEASE MODEL; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; SERODIAGNOSIS; SURVIVAL; VIROLOGY; VIRUS CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SURVIVAL ANALYSIS; VIRAL PLAQUE ASSAY;

EID: 84863669058     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001636     Document Type: Article

References (58)

1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-16.
2. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
3. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, et al. (1997) Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 176: 313-321.
4. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
5. Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, et al. (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229: 726-733.
6. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS, (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229-238.
7. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, et al. (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124: 485-493.
8. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
9. Modis Y, Ogata S, Clements D, Harrison SC, (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
10. Roehrig JT, (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
11. Mukhopadhyay S, Kuhn RJ, Rossmann MG, (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13-22.
12. Crill WD, Chang GJ, (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975-13986.
13. Gromowski GD, Barrett ND, Barrett AD, (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828-8837.
14. Roehrig JT, Bolin RA, Kelly RG, (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317-328.
15. Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, et al. (2009) On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90: 799-809.
16. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312-317.
17. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 12816-12826.
18. Halstead SB, (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476-481.
19. Gubler DJ, (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496.
20. Crill WD, Hughes HR, Delorey MJ, Chang GJ, (2009) Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4: e4991.
21. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
22. Schmidt AC, (2010) Response to dengue fever-the good, the bad, and the ugly? N Engl J Med 363: 484-487.
23. Halstead SB, O'Rourke EJ, (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265: 739-741.
24. Littaua R, Kurane I, Ennis FA, (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183-3186.
25. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, et al. (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176: 2825-2832.
26. Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, et al. (1998) Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72: 9729-9737.
27. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, et al. (2008) CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453: 672-676.
28. Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, et al. (2003) Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol 84: 2771-2779.
29. Chen YC, Huang HN, Lin CT, Chen YF, King CC, et al. (2007) Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol 14: 404-411.
30. Yu CY, Hsu YW, Liao CL, Lin YL, (2006) Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. J Virol 80: 11868-11880.
31. Durbin JE, Hackenmiller R, Simon MC, Levy DE, (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
32. Liu IJ, Chiu CY, Chen YC, Wu HC, (2011) Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem 286: 9726-9736.
33. Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, et al. (2003) Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306: 170-180.
34. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631-6643.
35. Dubel S, Breitling F, Fuchs P, Zewe M, Gotter S, et al. (1994) Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods 175: 89-95.
36. Orlandi R, Gussow DH, Jones PT, Winter G, (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A 86: 3833-3837.
37. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, et al. (2009) IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 37: D1006-1012.
38. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
39. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
40. Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM, (1982) Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg 31: 548-555.
41. Sabin AB, Schlesinger RW, (1945) Production of Immunity to Dengue with Virus Modified by Propagation in Mice. Science 101: 640-642.
42. Goncalvez AP, Purcell RH, Lai CJ, (2004) Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78: 12919-12928.
43. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823.
44. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84: 9227-9239.
45. Liu IJ, Hsueh PR, Lin CT, Chiu CY, Kao CL, et al. (2004) Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J Infect Dis 190: 797-809.
46. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, et al. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 86: 4220-4224.
47. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, et al. (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A 91: 969-973.
48. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427.
49. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, et al. (2007) Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins 68: 294-304.
50. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11: 522-530.
51. Wu HC, Huang YL, Chao TT, Jan JT, Huang JL, et al. (2001) Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol 39: 977-982.
52. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM, (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103-113.
53. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80: 6982-6992.
54. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188.
55. Goncalvez AP, Chien CH, Tubthong K, Gorshkova I, Roll C, et al. (2008) Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 82: 7009-7021.
56. Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, et al. (2007) Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 81: 12766-12774.
57. Sultana H, Foellmer HG, Neelakanta G, Oliphant T, Engle M, et al. (2009) Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol 183: 650-660.
58. Yauch LE, Shresta S, (2008) Mouse models of dengue virus infection and disease. Antiviral Res 80: 87-93.